Organization Profile

You just read:

Resverlogix Completes Dosing of RVX-208 in SUSTAIN, a Phase 2b Clinical Trial Targeting High-Risk Cardiovascular Disease Patients

News provided by

Resverlogix Corp.

May 09, 2012, 14:12 ET